Page 127 - ESHRE2019
P. 127
Clinical trials with hESC-derivatives Severe heart failure
First patient: Evaluated at 3 month for functional status improvement
• norejection
• noadverseeffects
Clinical trials with hESC-derivatives Severe heart failure
Menasche et al, 2018
- 6 patients; median of 18 months of follow-up
PCC Stem Cells - ESHRE Vienna 2019
- Population of cardiovascular progenitors: 97,5%
Intraoperative Views of Implantation of the Cardiovascular Progenitor‐Loaded Fibrin Patch
- One death post-operatively from treatment-unrelated comorbidities
- Uneventful recoveries
- No tumors and no arrhytmias
- All patients were symptomatically improved with an increased
systolic motion
- Three patients developed clinical silent alloinmunization
- One patient died of heart failure after 22 months
PCC Stem Cells - ESHRE Vienna 2019
Intraoperative views of implantation of the cardiovascular progenitor- loaded fibrin patch
122
PRECONGRESS COURSE 13 I VIENNA, AUSTRIA – 23 JUNE 2019 125
